BMRN May 2024 120.000 call
OPR - OPR Delayed Price. Currency in USD
Add to watchlist
As of 10:33AM EDT. Market open.
| Previous Close | 0.3500 |
| Open | N/A |
| Bid | 0.0000 |
| Ask | 0.5000 |
| Strike | 120.00 |
| Expire Date | 2024-05-17 |
| Day's Range | 0.3500 - 0.3500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 10 |
ZacksZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
GuruFocus.comInsider Sale: EVP, Chief Commercial Officer Jeffrey Ajer Sells 5,000 Shares of Biomarin ...
On May 2, 2024, Jeffrey Ajer, the Executive Vice President and Chief Commercial Officer of Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 5,000 shares of the company.
Zacks5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
© 2024 Yahoo. All rights reserved.